Avacta eyes key clinical milestones after strengthening balance sheet

 Avacta is entering the second half of 2026 with a strengthened financial position, advancing clinical programmes and ongoing discussions with potential commercial partners.

In a trading and business update ahead of today's annual general meeting, the AIM-listed life sciences business said it had extended its cash runway into early 2027 after raising £41.5m over the past 18 months.

Chief executive Christina Coughlin said the company had made 'strong... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...